Adjuvant hormonal treatment with peptide YY or its analog decreases human pancreatic carcinoma growth

Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY). We examined whether adjuvant treatment with PYY or its synthetic analog, BIM-43004, would decrease human pancreatic adenocarcinoma growth. Human pancreatic ductal adenocarcinomas, MiaPaCa-2...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 1996, Vol.171 (1), p.192-196
Main Authors: Liu, Carson D., Rongione, Anthony J., Garvey, Laura, Balasubramaniam, Ambipaikan, McFadden, David W.
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adenocarcinoma
Cancer
Carcinoma, Ductal, Breast - pathology
Cell growth
Cell membranes
Chemotherapy
Epidermal growth factor
Fluorouracil - pharmacology
Gastrointestinal Hormones - pharmacology
Growth factors
Humans
Leucovorin - pharmacology
Pancreatic cancer
Pancreatic carcinoma
Pancreatic Neoplasms - pathology
Peptide YY
Peptides
Peptides - pharmacology
Receptor, Epidermal Growth Factor - analysis
Receptors
Tumor Cells, Cultured
Western blotting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have revealed decreased pancreatic cancer cell growth upon administration of peptide YY (PYY). We examined whether adjuvant treatment with PYY or its synthetic analog, BIM-43004, would decrease human pancreatic adenocarcinoma growth. Human pancreatic ductal adenocarcinomas, MiaPaCa-2 and BxPC-3, were cultured and assessed for growth by MTT assay. Pancreatic cancer cells received 500 pmol of PYY or BIM-43004 for 24 hours prior to 5-fluorouracil (5-FU; 10 ug/mL) and leucovorin (40 Mg/mL) administration. Cell membrane epidermal growth factor (EGF) receptors were analyzed by Western blotting after exposure to peptides and chemotherapy. Cancer cell growth was reduced in all groups receiving hormonal pretreatment (23% PYY/5-FU/leucovorin versus control; 27% BIM-43004/5-FU/leucovorin versus control) as compared with groups receiving 5-FU and leucovorin only (16% versus control). The EGF receptor expression was reduced by 30% in cells treated with PYY/5-FU/leucovorin and by 45% in cells treated with BIM/5-FU/leucovorin as compared with control cells without treatment. Human pancreatic cancer cell growth is further decreased when pretreated with PYY or its synthetic analog prior to chemotherapy. Am J Surg. 1996;171; 192–196.
ISSN:0002-9610
1879-1883
DOI:10.1016/S0002-9610(99)80098-1